Page last updated: 2024-09-04
tipifarnib and ATLL
tipifarnib has been researched along with ATLL in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Eckhardt, SG; Landau, HJ; Lockerbie, RO; Medeiros, BC; Morrow, M; Pitts, T | 1 |
Other Studies
1 other study(ies) available for tipifarnib and ATLL
| Article | Year |
|---|---|
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Line, Tumor; Clone Cells; Farnesyltranstransferase; Humans; Leukemia-Lymphoma, Adult T-Cell; Quinolones; Verapamil | 2007 |